Show simple item record

dc.contributor.authorSisteré-Oró, Marta
dc.contributor.authorPedersen, Gabriel K.
dc.contributor.authorCórdoba, Lorena
dc.contributor.authorLópez-Serrano, Sergi
dc.contributor.authorChristensen, Dennis
dc.contributor.authorDarji, Ayub
dc.contributor.otherProducció Animalca
dc.date.accessioned2020-07-06T10:54:08Z
dc.date.available2020-07-06T10:54:08Z
dc.date.issued2020-04-20
dc.identifier.citationSisteré-Oró, Marta, Gabriel K. Pedersen, Lorena Córdoba, Sergi López-Serrano, Dennis Christensen, and Ayub Darji. 2020. "Influenza NG-34 T Cell Conserved Epitope Adjuvanted With CAF01 As A Possible Influenza Vaccine Candidate". Veterinary Research 51 (1). doi:10.1186/s13567-020-00770-4.ca
dc.identifier.issn0928-4249ca
dc.identifier.urihttp://hdl.handle.net/20.500.12327/866
dc.description.abstractConserved epitopes are targets commonly researched to be part of universal vaccine candidates against influenza viruses (IV). These conserved epitopes need to be cross-protecting against distinct IV subtypes and to have a strong immunogenic potential. Nevertheless, subunit vaccines generally require a strong adjuvant to enhance their immunological effects. Herewith, we compare four different adjuvants differing in their immunological signatures that may enhance efficacy of a conserved hemagglutinin (HA)-epitope from IV, the NG-34, to define the most efficient combination of antigen/adjuvant to combat IV infections. Soluble NG-34 was mixed with adjuvants like aluminium hydroxide (AH) and AddaVax, known to induce Th2 and humoral responses; CAF01 which displays a biased Th1/Th17 profile and Diluvac Forte which augments the humoral response. Combinations were tested in different groups of mice which were subjected to immunological analyses. CAF01 + NG-34 induced a complete immune response with the highest IgG1, IgG2c titers and percentages of activated CD4 T cell promoting IFN-γ, IL-2 and TNF-α producing cells. Furthermore, in NG-34 stimulated mice splenocytes, cytokine levels of IFN-γ, IL-1β, IL-6, IL-10, IL-17 and TNF-α were also the highest in the CAF01 + NG-34 mouse group. This complete induced immune response covering the humoral and the cellular arms of the adaptive immunity promoted by CAF01 + NG-34 group suggests that CAF01 could be a good candidate as an adjuvant to combine with NG-34 for an efficacious vaccine against IV. However, more studies performed in IV hosts as well as studies with a challenge model are further required.ca
dc.format.extent11ca
dc.language.isoengca
dc.publisherBMCca
dc.relation.ispartofVeterinary Researchca
dc.rightsAttribution 4.0 Internationalca
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleInfluenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidateca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.relation.projectIDEC/H2020/730964/ES/European Vaccine Research and Development Infrastructure/TRANSVAC2ca
dc.relation.projectIDMINECO/Programa estatal de I+D+I orientada a los retos de la sociedad/AGL2013-48923-C2-2-R/ES/Nuevas estrategias vacunales frente a enfermedades víricas ganaderas empleando pseudopartículas virales modificadas/ca
dc.subject.udc619ca
dc.identifier.doihttps://doi.org/10.1186/s13567-020-00770-4ca
dc.contributor.groupSanitat Animalca


Files in this item

 
 

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/